697 related articles for article (PubMed ID: 30809307)
1. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
2. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
3. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
4. TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.
Good CR; Panjarian S; Kelly AD; Madzo J; Patel B; Jelinek J; Issa JJ
Cancer Res; 2018 Aug; 78(15):4126-4137. PubMed ID: 29891505
[TBL] [Abstract][Full Text] [Related]
5. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
[TBL] [Abstract][Full Text] [Related]
6. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
[TBL] [Abstract][Full Text] [Related]
7. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells.
Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z
Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257
[TBL] [Abstract][Full Text] [Related]
8. Role of TET1 and 5hmC in an Obesity-Linked Pathway Driving Cancer Stem Cells in Triple-Negative Breast Cancer.
Bao B; Teslow EA; Mitrea C; Boerner JL; Dyson G; Bollig-Fischer A
Mol Cancer Res; 2020 Dec; 18(12):1803-1814. PubMed ID: 32913111
[TBL] [Abstract][Full Text] [Related]
9. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
10. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
11. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
12. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.
Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z
Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937
[TBL] [Abstract][Full Text] [Related]
13. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
15. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
16. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
17. (-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.
Ying L; Yan F; Williams BR; Xu P; Li X; Zhao Y; Hu Y; Wang Y; Xu D; Dai J
Clin Exp Pharmacol Physiol; 2018 Jan; 45(1):58-67. PubMed ID: 28925507
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Deblois G; Tonekaboni SAM; Grillo G; Martinez C; Kao YI; Tai F; Ettayebi I; Fortier AM; Savage P; Fedor AN; Liu X; Guilhamon P; Lima-Fernandes E; Murison A; Kuasne H; Ba-Alawi W; Cescon DW; Arrowsmith CH; De Carvalho DD; Haibe-Kains B; Locasale JW; Park M; Lupien M
Cancer Discov; 2020 Sep; 10(9):1312-1329. PubMed ID: 32546577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
